Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
-
Published:2023-06
Issue:
Volume:60
Page:102016
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Oliva Stefania, Genuardi Elisa, Paris Laura, D'Agostino Mattia, Rogers Jennifer, Rota-Scalabrini Delia, Jacob Allison P.ORCID, Patriarca Francesca, Luppi Mario, Bertazzoni Paola, Velluti Cristina, Capra Andrea, Saraci Elona, Rossi Marco, Allegra Alessandro, Mina Roberto, Gentile Massimo, Kirsch Ilan R., Belotti Angelo, Cavo Michele, Bruno Benedetto, Musto Pellegrino, Boccadoro Mario, Zamagni Elena, Gay FrancescaORCID
Reference41 articles.
1. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma;Facon;N Engl J Med,2019 2. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma;Mateos;N Engl J Med,2018 3. Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVd) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): griffin study update;Voorhees;Blood,2019 4. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study;Moreau;Lancet,2019 5. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE;San-Miguel;Blood,2022
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|